DOCHealthpeak Properties
Healthpeak Properties, Inc. is a Standard & Poor’s (“S&P”) 500 company that owns, operates, and develops high-quality real estate focused on healthcare discovery and delivery in the United States (“U.S.”). 10-K, Item 1
- Headquarters
- Denver, CO
- CEO
- Scott M. Brinker
- Next results
- around Feb 1, 2027
The numbers DOC said it expected, in its earnings releases of the last 3 years, next to what it then reported for the same period. Each target links to the sentence in the release; each result to the 10-Q or 10-K it was first reported in.
Of 1 range targets with a reported result: 1 came in above the last range given, 0 within it, 0 below it.
| Target | What the company said | Reported | Result |
|---|---|---|---|
| Diluted EPS (company-defined) Fiscal 2026 |
Given $1.70 to $1.74 release 2026-02-02
|
– | No standard number |
The company's wordsFor the full year 2026, we have established the following guidance ranges: … Diluted FFO as Adjusted per share of $1.70 – $1.74 release 2026-02-02 | |||
| FFO per share (company-defined) Fiscal 2026 |
Given $1.70 to $1.74 release 2026-02-02
|
– | No standard number |
The company's wordsFor the full year 2026, we have established the following guidance ranges: … Diluted Nareit FFO per share of $1.70 – $1.74 release 2026-02-02 | |||
| Diluted EPS (company-defined) Fiscal 2025 (ended 2025-12-31) |
Given $1.81 to $1.87 release 2025-02-03
Kept $1.81 to $1.87 release 2025-04-24
Kept $1.81 to $1.87 release 2025-07-24
Kept $1.81 to $1.87 release 2025-10-23
|
– | No standard number |
The company's wordsFor full year 2025, we have established the following Guidance ranges: … Diluted FFO as Adjusted per share of $1.81 – $1.87 release 2025-02-03 We are reaffirming the following guidance ranges for full year 2025: … Diluted FFO as Adjusted per share of $1.81 – $1.87 release 2025-04-24 We are reaffirming the following guidance ranges for full year 2025: … Diluted FFO as Adjusted per share of $1.81 – $1.87 release 2025-07-24 We are reaffirming the following guidance ranges for full year 2025: … Diluted FFO as Adjusted per share of $1.81 – $1.87 release 2025-10-23 | |||
| FFO per share (company-defined) Fiscal 2025 (ended 2025-12-31) |
Given $1.81 to $1.87 release 2025-02-03
Kept $1.81 to $1.87 release 2025-04-24
Lowered $1.78 to $1.84 release 2025-10-23
|
– | No standard number |
The company's wordsFor full year 2025, we have established the following Guidance ranges: … Diluted Nareit FFO per share of $1.81 – $1.87 release 2025-02-03 We are reaffirming the following guidance ranges for full year 2025: … Diluted Nareit FFO per share of $1.81 – $1.87 release 2025-04-24 We are reaffirming the following guidance ranges for full year 2025: … Diluted Nareit FFO per share of $1.78 – $1.84 release 2025-10-23 | |||
| Diluted EPS (company-defined) Fiscal 2024 (ended 2024-12-31) |
Given $1.73 to $1.79 release 2024-02-08
|
– | No standard number |
The company's wordsFor full year 2024, we have established the following outlook ranges, which are inclusive of the impact from the Physicians Realty Trust merger: … Diluted FFO as Adjusted per share of $1.73 – $1.79 release 2024-02-08 | |||
| Diluted EPS Fiscal 2024 (ended 2024-12-31) |
Given $0.16 to $0.20 release 2024-04-25
Raised $0.27 to $0.31 release 2024-07-25
|
$0.36 10-K filed 2025-02-04 |
Above the range |
The company's words– Increased full year 2024 diluted earnings guidance to a range of $0.16 – $0.20 per share; increased the midpoint of 2024 FFO as Adjusted and AFFO guidance by +$0.02 per share, respectively and increased Total Merger-Combined Same-Store Cash (Adjusted) NOI growth guidance by 25 basis points at the midpoint release 2024-04-25 – Increased full year 2024 diluted earnings guidance to a range of $0.27 – $0.31 per share; increased the midpoint of each 2024 FFO as Adjusted and AFFO guidance by +$0.01 per share, and increased Total Merger-Combined Same-Store Cash (Adjusted) NOI growth guidance by 25 basis points at the midpoint release 2024-07-25 | |||
| AFFO per share (company-defined) Fiscal 2024 (ended 2024-12-31) |
Given $1.50 to $1.56 release 2024-02-08
|
– | No standard number |
The company's wordsFor full year 2024, we have established the following outlook ranges, which are inclusive of the impact from the Physicians Realty Trust merger: … Diluted AFFO per share of $1.50 – $1.56 release 2024-02-08 | |||
| FFO per share (company-defined) Fiscal 2024 (ended 2024-12-31) |
Given $1.54 to $1.60 release 2024-02-08
|
– | No standard number |
The company's wordsFor full year 2024, we have established the following outlook ranges, which are inclusive of the impact from the Physicians Realty Trust merger: … Diluted Nareit FFO per share of $1.54 – $1.60 release 2024-02-08 | |||
1 target far from the company's reported total, so not compared (usually a target for one product, segment or definition)
- Diluted EPS, Fiscal 2025 (ended 2025-12-31): said $0.30 to $0.36, reported $0.10. The company's words
Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (12 releases since 2024-02-08), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.
Work on DOC in a spreadsheet:
Excel workbook (a sheet per section, ten years by column, charts, links to the filings) ·
CSV.
For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/DOC/export.csv") into a cell.